Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2

Status

Recruiting 32Not yet recruiting 8Active not recruiting 6Terminated 5Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Other solid neoplasm 5Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 44Breast Neoplasms 33Neoplasms 31Melanoma 24Neoplasm Metastasis 22Leukemia, Myeloid, Acute 21Colorectal Neoplasms 18Prostatic Neoplasms 17Multiple Myeloma 17Lung Neoplasms 17Ovarian Neoplasms 14Myelodysplastic Syndromes 13Squamous Cell Carcinoma of Head and Neck 12Recurrence 12Lymphoma, Non-Hodgkin 12Carcinoma, Renal Cell 11Uterine Cervical Neoplasms 10Urinary Bladder Neoplasms 10Pancreatic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Glioblastoma 10Brain Neoplasms 10Carcinoma, Hepatocellular 9Stomach Neoplasms 8Triple Negative Breast Neoplasms 7Rectal Neoplasms 7Lymphoma 7Hodgkin Disease 7Head and Neck Neoplasms 7Glioma 7

Interventions

sotorasib 1serabelisib 1olaparib 1mirdametinib 1adagrasib 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Terminated × Advanced Solid Tumor × 90 days × Clear all
NCT06685068 2026-05-08

A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors

Genmab

Phase 1/2 Terminated
23 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05580770 2026-05-01

Mirdametinib + BGB-3245 in Advanced Solid Tumors

SpringWorks Therapeutics, Inc.

Phase 1/2 Terminated
23 enrolled 22 charts
Other solid neoplasm

Advanced Solid Tumor

NCT05300048 2026-04-30

Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations

Faeth Therapeutics

Phase 1 Terminated
34 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05036291 2026-04-22

A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Ningbo Newbay Technology Development Co., Ltd

Phase 1 Terminated
25 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT06130254 2026-04-09

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

M.D. Anderson Cancer Center

Phase 1 Terminated
1 enrolled
Other solid neoplasmThoracic

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡